InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
5
T+90 hit rate
0%
T+90 mean return
-53.1%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Mahadevia Ankit, Chairman & CEO. Insider active across 1 company, notably Spero Therapeutics, Inc.. In total, 14 disclosures have been published. Split: 0 buy · 5 sells. Total volume traded: €129k. History available since 26 August 2021. The latest transaction was disclosed on 5 February 2025 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
13,959 shares@ US$0.784.9% of flowCommon StockSEC:0000950170-25-014849:0
5,912 shares@ US$1.353.4% of flowCommon StockSEC:0000950170-24-102000:0
20,000 shares0Common StockSEC:0000950170-24-066625:0
63,795 shares@ US$1.3737.9% of flowCommon StockSEC:0000950170-24-011496:0
20,000 shares0Common StockSEC:0000950170-23-052692:0
9,040 shares@ US$1.265.0% of flowCommon StockSEC:0000950170-23-045442:0
12,286 shares@ US$1.819.6% of flowCommon StockSEC:0000899243-23-004039:0
531,914 shares0Common StockSEC:0000899243-23-003939:0
134,168 shares0Common StockSEC:0000899243-22-004591:0
134,168 shares0Common StockSEC:0000899243-22-004591
8,000 shares@ US$5.9019.6% of flowCommon StockSEC:0000899243-21-050049
8,000 shares@ US$5.900.032% mcap50.0% of flowCommon StockSEC:0000899243-21-050049:0
78,219 shares0Common StockSEC:0000899243-21-034502:0
78,219 shares0Common StockSEC:0000899243-21-034502
14 of 14 declarations
About Mahadevia Ankit
Mahadevia Ankit is the Chairman and CEO of Spero Therapeutics, Inc. He leads the company with a vision focused on innovation in developing treatments for rare diseases. His leadership is essential in guiding Spero's research and development efforts.
